modified release oral dosage forms Archives

Introduction to the Formulation and Design of Multiunit Particulate Systems

Formulation and design of multiunit particulate systems focus on oral dosage forms that contain many small, functional subunits instead of one single unit. These systems typically consist of pellets, granules, or coated spheres that are filled into capsules or compressed into tablets. As a result, they allow precise control of drug release and improved robustness during gastrointestinal transit. Moreover, the formulation and design of multiunit particulate systems emphasize a deep understanding of materials, coating technologies, and compression behavior. Therefore, developers can protect sensitive drug layers while ensuring consistent performance. In recent years, Quality by Design approaches have further strengthened this concept by linking formulation variables directly to product quality and clinical relevance.

Functionality and Consumer Compliance Opportunities of Multiunit Particulate Systems

Multiunit particulate systems offer clear functional advantages that directly support consumer compliance. First, the multiparticulate structure distributes the drug dose along the gastrointestinal tract, which improves absorption consistency. In addition, this distribution reduces local irritation and lowers the clinical risk of dose dumping. Furthermore, these systems often improve swallowability because the individual subunits are small and well tolerated. Consequently, patient groups such as children and older adults benefit significantly. At the same time, multiunit particulate systems enable flexible dosing and advanced release profiles. Therefore, they align better with daily routines and long-term treatment needs, which ultimately enhances adherence.

Formulation and Design of Multiunit Particulate Systems

Summary of the Pantoprazole MUPS Tablet Study

The referenced publication examines the formulation and design of multiunit particulate systems (MUPS) through the development of a pantoprazole MUPS tablet using a Quality by Design framework. The study aimed to understand how selected formulation variables affect critical tablet characteristics. To achieve this, the authors used enteric-coated pantoprazole pellets as multiparticulate units and compressed them into tablets with protective excipients. As a result, the formulation needed to balance mechanical strength with coating integrity.

The researchers applied a factorial design of experiments to evaluate three key variables: dry polymer content, matrix-forming polymer concentration, and pellet loading. Subsequently, they measured responses such as dissolution behavior, tablet hardness, friability, and disintegration time. The results showed that each variable influenced tablet quality in a measurable way. For example, higher pellet content increased the risk of coating damage during compression. However, appropriate polymer levels reduced this risk and stabilized drug release.

Based on statistical analysis, the study defined an optimized design space that delivered robust tablets with acceptable mechanical properties. In addition, the optimized formulation demonstrated dissolution behavior comparable to a marketed reference product. Therefore, the study confirmed that a well-designed multiunit particulate system can deliver pantoprazole effectively without compromising enteric protection. Overall, the work highlights how systematic formulation control improves both product performance and development efficiency.

Role of MCC Spheres in the Multiunit Particulate System

MCC spheres (such as CELLETS® 150-300) played a central role as inert starter cores in the multiparticulate formulation. First, they provided a uniform and mechanically stable substrate for drug layering. Moreover, their spherical shape supported homogeneous coating and predictable dissolution behavior. During compression, MCC spheres showed favorable plastic deformation, which helped absorb mechanical stress. As a result, they protected the enteric coating from cracking or rupture. Consequently, MCC spheres enabled the successful conversion of coated pellets into a compressed MUPS tablet while maintaining functional integrity.

Conclusion and Outlook

In conclusion, formulation and design of multiunit particulate systems offer a robust strategy for developing patient-friendly oral dosage forms. The pantoprazole study clearly demonstrates how a Quality by Design approach links formulation variables to tablet performance. Moreover, the use of MCC spheres highlights the importance of selecting suitable core materials for compression stability. Looking ahead, advances in material science and process understanding will further strengthen multiunit particulate systems. Therefore, these systems will continue to play a key role in improving therapeutic consistency and consumer compliance.

References

[1] G.S. Sonar, S. Rawat, International Journal of PharmTech Research, CODEN (USA): IJPRIF, ISSN: 0974-4304, Vol.8, No.8, pp 05-23, 2015. (link)

Introduction to delayed release oral pharmaceutical compositions

Delayed release oral pharmaceutical compositions enable drug delivery at a defined time after oral administration. Unlike immediate release dosage forms, these systems control when the active pharmaceutical ingredient becomes available for absorption. As a result, they protect acid-sensitive drugs and allow targeted delivery to specific gastrointestinal regions. Moreover, delayed release forms can reduce gastric irritation and peak-related side effects. Therefore, they often improve patient tolerance and adherence. From a consumer compliance perspective, these formulations support simplified dosing schedules and more predictable therapeutic effects. Consequently, they play a key role in chronic therapies that demand long-term adherence and consistent drug exposure.

Summary of US12521351B1: delayed release oral pharmaceutical compositions

The patent US12521351B1 describes delayed release oral pharmaceutical compositions designed primarily for treating inflammatory bowel disease. Specifically, the invention focuses on multiparticulate systems containing mesalamine and hyaluronan within an oral capsule. These particles use an inert core that serves as a substrate for successive functional layers. First, a mesalamine-containing drug layer is applied. Next, a hyaluronan layer follows, which contributes both therapeutic and release-modifying functions. Finally, an outer coating controls the onset of drug release in the gastrointestinal tract.

Importantly, the patent emphasizes controlled release timing rather than simple gastro-resistance. The coating system delays drug exposure until the dosage form reaches intestinal regions associated with inflammation. As a result, the formulation minimizes drug loss in the stomach and improves local efficacy. Furthermore, the multiparticulate design allows uniform drug distribution throughout the intestine, which reduces variability in drug exposure.

In addition, the patent outlines manufacturing methods such as fluid-bed coating and encapsulation. These processes ensure reproducible layer thickness and particle size distribution. Consequently, the formulations achieve consistent dissolution behavior across batches. The patent also defines preferred ranges for core size, drug load, and coating thickness. Therefore, it provides a framework for scalable industrial production.

Overall, US12521351B1 demonstrates how delayed release oral pharmaceutical compositions can combine therapeutic targeting with patient-friendly oral delivery. By integrating functional excipients and structured layering, the invention advances existing mesalamine therapies toward improved clinical performance.

Technical considerations and formulation context

Delayed release oral drug forms differ fundamentally from uncontrolled release systems. While immediate release products dissolve rapidly after ingestion, delayed release formulations intentionally suppress early dissolution. Consequently, they reduce exposure in the stomach and shift drug availability to later intestinal segments. This distinction becomes critical for drugs that cause gastric irritation or degrade in acidic environments.

Dissolution profiles represent a central design parameter. Ideally, delayed release systems show minimal drug release under acidic conditions. Then, they exhibit a rapid and reproducible release once intestinal pH thresholds are reached. Therefore, formulators must carefully balance coating composition, thickness, and particle size. In addition, variability in gastrointestinal transit times must be considered during development.

However, delayed release formulations face several obstacles. Uniform coating of multiparticulates remains technically demanding. Moreover, small variations in process parameters can significantly affect release kinetics. Stability during storage also presents challenges, especially for moisture-sensitive coatings. As a result, robust process control and extensive dissolution testing are essential.

Within this patent context, CELLETS® 500 play a supportive yet important role. These microcrystalline cellulose starter cores provide a smooth, inert, and size-defined substrate. Consequently, they enable uniform drug layering and coating application. Their narrow particle size distribution improves batch reproducibility and dissolution consistency. Therefore, CELLETS® 500 contribute directly to the functional reliability of delayed release oral pharmaceutical compositions.

Conclusion and outlook

Delayed release oral pharmaceutical compositions continue to shape modern oral drug delivery. They align pharmacokinetics with disease physiology and patient needs. The US12521351B1 patent illustrates how structured multiparticulate systems can enhance intestinal targeting and therapeutic consistency. Looking ahead, advances in coating polymers, starter core technologies, and process analytics will further refine these formulations. Consequently, delayed release oral pharmaceutical compositions will remain central to improving efficacy, safety, and long-term patient compliance in oral therapies.

Patent Summary

Name of Patent: Delayed release oral pharmaceutical composition
Patent Number: US12521351B1
Year of Patent: 2026
Patent Holders: Tsung-Chung Wu, Yu-Chih Chen
Affiliation: Aihol Corp

Posts

Formulation and design of multiunit particulate systems